13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001789778
Total reported value
$158.8M
$158.8M
8 檔
61.1%
According to the latest 13F quarterly dataset, Blue Water Life Science Advisors, LP managed an equity portfolio of $158.8M at the end of Q3 2024, spanning 8 distinct U.S. exchange-listed positions.
Blue Water Life Science Advisors, LP executed strategic sector rebalancing during Q3 2024, establishing 2 new positions while fully exiting 2 holdings and trimming 3 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | NTRA | Natera Inc | Stock-Healthcare | 32.50% | -1.28% | -42.14% | |
| 2 | CDNA | Caredx Inc | Stock-Other | 16.59% | +8.34% | +18.43% | |
| 3 | EXK | Exact Sciences CORP | Stock-Materials | 15.29% | — | +345.12% | |
| 4 | ✓ | Akoya Biosciences Inc | Stock-Other | 11.24% | — | — | |
| 5 | ADPT | Adaptive Biotechnologies | Stock-Other | 9.66% | +2.41% | — | |
| 6 | GH | Guardant Health Inc | Stock-Healthcare | 9.10% | -7.10% | -21.01% | |
| 7 | PSNL | Personalis Inc | Stock-Other | 4.73% | +5.59% | — | |
| 8 | QTRX | Quanterix CORP | Stock-Other | 0.89% | +3.40% | -71.84% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | EXK | Exact Sciences CORP | +12.9% | +345.12% | Add |
| 2 | ADPT | Adaptive Biotechnologies | +9.7% | NEW | New buy |
| 3 | CDNA | Caredx Inc | +8.9% | +18.43% | Add |
| 4 | PSNL | Personalis Inc | +4.7% | NEW | New buy |
| 5 | ✓ | Akoya Biosciences Inc | +0.6% | — | Unchanged |
| 6 | MXCT | Maxcyte Inc | -2.3% | EXIT | Sold out |
| 7 | QTRX | Quanterix CORP | -2.7% | -71.84% | Trim |
| 8 | TXG | 10x Genomics Inc-class A | -4.4% | EXIT | Sold out |
| 9 | GH | Guardant Health Inc | -6.9% | -21.01% | Trim |
| 10 | NTRA | Natera Inc | -20.5% | -42.14% | Trim |
According to official SEC Form 13F filings, Blue Water Life Science Advisors, LP reported a total U.S. public equity portfolio value of $158.8M across 8 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including NTRA, CDNA, EXK) accounted for 61.1% of total reported equity market value during Q3 2024.
Top New Position Initiated
ADPT
市值: $11.0M
Top Position Liquidated / Trimmed
TXG
前期市值: $4.5M
During Q3 2024, Blue Water Life Science Advisors, LP's top holdings by market value included NTRA (32.5%)、CDNA (16.6%)、EXK (15.3%). The largest single position, NTRA, represented 32.5% of total portfolio value.
In Q3 2024, Blue Water Life Science Advisors, LP made 9 total portfolio adjustments, initiating 2 new buys, adding to 2 positions, trimming 3 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.